SUN PRAIRIE, Wis. (August 21, 2020) – Ventris Learning, LLC and Simucase, LLC announced a strategic co-marketing relationship that promotes Simucase and Ventris’ Diagnostic Evaluation of Language Variation – DELV(tm)-Screening Test (ST), DELV(tm)-Norm Referenced (NR) test (DELV, 2018), and Assessment of Literacy & Language (ALL(tm)).
“The DELV tests were designed to be linguistically unbiased for students who speak non-mainstream linguistic systems such as African American English,” said Katie Ondo, Simucase Editor in Chief. “Simucase is excited to add simulation experiences for students and professionals to practice administering the DELV tests with virtual patients.”
“The Simucase simulations will help speech-language pathologists better understand how to interpret the unique DELV’s unique profile of each child’s linguistic strengths and weaknesses,” said Robert Meyer, Ventris president. “In addition to the DELV, the ALL is a new assessment being released this month that is also included in the partnership. The ALL is used to screen and diagnose language impairment along with emergent literacy skills for children ages 4.0-6.11.
Simucase is the leading developer of clinical simulations in the field of speech-language pathology, audiology, occupational therapy and recently launched physical therapy. Simucase’s patented technology allows users to assess, diagnose, make recommendations, and provide intervention for virtual patients. To learn more, visit http://www.simucase.com.
About Ventris Learning
Ventris Learning’s linguistically responsive supplemental teaching and assessment resources support teachers to better meet the instructional needs of students underserved in literacy. To learn more, visit www.ventrislearning.com.
Ventris Learning Publisher
1 (888) 439-6699
Simucase Editor in Chief